191 related articles for article (PubMed ID: 19114307)
1. Spiro-piperidine azetidinones as potent TRPV1 antagonists.
Xiao D; Palani A; Aslanian R; McKittrick BA; McPhail AT; Correll CC; Phelps PT; Anthes JC; Rindgen D
Bioorg Med Chem Lett; 2009 Feb; 19(3):783-7. PubMed ID: 19114307
[TBL] [Abstract][Full Text] [Related]
2. Discovery of piperidine carboxamide TRPV1 antagonists.
Cheung WS; Calvo RR; Tounge BA; Zhang SP; Stone DR; Brandt MR; Hutchinson T; Flores CM; Player MR
Bioorg Med Chem Lett; 2008 Aug; 18(16):4569-72. PubMed ID: 18662879
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of 6-phenylnicotinamide derivatives as antagonists of TRPV1.
Westaway SM; Thompson M; Rami HK; Stemp G; Trouw LS; Mitchell DJ; Seal JT; Medhurst SJ; Lappin SC; Biggs J; Wright J; Arpino S; Jerman JC; Cryan JE; Holland V; Winborn KY; Coleman T; Stevens AJ; Davis JB; Gunthorpe MJ
Bioorg Med Chem Lett; 2008 Oct; 18(20):5609-13. PubMed ID: 18809327
[TBL] [Abstract][Full Text] [Related]
4. Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profiles.
McAtee JJ; Dodson JW; Dowdell SE; Erhard K; Girard GR; Goodman KB; Hilfiker MA; Jin J; Sehon CA; Sha D; Shi D; Wang F; Wang GZ; Wang N; Wang Y; Viet AQ; Yuan CC; Zhang D; Aiyar NV; Behm DJ; Carballo LH; Evans CA; Fries HE; Nagilla R; Roethke TJ; Xu X; Douglas SA; Neeb MJ
Bioorg Med Chem Lett; 2008 Jul; 18(13):3716-9. PubMed ID: 18524591
[TBL] [Abstract][Full Text] [Related]
5. T-type calcium channel blockers: spiro-piperidine azetidines and azetidinones-optimization, design and synthesis.
Smith EM; Sorota S; Kim HM; McKittrick BA; Nechuta TL; Bennett C; Knutson C; Burnett DA; Kieselgof J; Tan Z; Rindgen D; Bridal T; Zhou X; Jia YP; Dong Z; Mullins D; Zhang X; Priestley T; Correll CC; Tulshian D; Czarniecki M; Greenlee WJ
Bioorg Med Chem Lett; 2010 Aug; 20(15):4602-6. PubMed ID: 20580233
[TBL] [Abstract][Full Text] [Related]
6. Synthesis of spiro[chroman-2,4'-piperidin]-4-one derivatives as acetyl-CoA carboxylase inhibitors.
Shinde P; Srivastava SK; Odedara R; Tuli D; Munshi S; Patel J; Zambad SP; Sonawane R; Gupta RC; Chauthaiwale V; Dutt C
Bioorg Med Chem Lett; 2009 Feb; 19(3):949-53. PubMed ID: 19097787
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationship (SAR) investigations of substituted imidazole analogs as TRPV1 antagonists.
Gore VK; Ma VV; Tamir R; Gavva NR; Treanor JJ; Norman MH
Bioorg Med Chem Lett; 2007 Nov; 17(21):5825-30. PubMed ID: 17851073
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and evaluation of 4-alkoxy-[1'-cyclobutyl-spiro(3,4-dihydrobenzopyran-2,4'-piperidine)] analogues as histamine-3 receptor antagonists.
Becknell NC; Dandu RR; Lyons JA; Aimone LD; Raddatz R; Hudkins RL
Bioorg Med Chem Lett; 2012 Jan; 22(1):186-9. PubMed ID: 22153342
[TBL] [Abstract][Full Text] [Related]
9. 4-(2-Pyridyl)piperazine-1-benzimidazoles as potent TRPV1 antagonists.
Shao B; Huang J; Sun Q; Valenzano KJ; Schmid L; Nolan S
Bioorg Med Chem Lett; 2005 Feb; 15(3):719-23. PubMed ID: 15664844
[TBL] [Abstract][Full Text] [Related]
10. Trisubstituted pyrimidines as transient receptor potential vanilloid 1 (TRPV1) antagonists with improved solubility.
Wang X; Chakrabarti PP; Ognyanov VI; Pettus LH; Tamir R; Tan H; Tang P; Treanor JJ; Gavva NR; Norman MH
Bioorg Med Chem Lett; 2007 Dec; 17(23):6539-45. PubMed ID: 17937985
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological evaluation of novel diarylalkyl amides as TRPV1 antagonists.
Li FN; Kim NJ; Paek SM; Kwon DY; Min KH; Jeong YS; Kim SY; Park YH; Kim HD; Park HG; Suh YG
Bioorg Med Chem; 2009 May; 17(10):3557-67. PubMed ID: 19398205
[TBL] [Abstract][Full Text] [Related]
12. Discovery of TRPV1 antagonist ABT-116.
Brown BS; Keddy R; Perner RJ; DiDomenico S; Koenig JR; Jinkerson TK; Hannick SM; McDonald HA; Bianchi BR; Honore P; Puttfarcken PS; Moreland RB; Marsh KC; Faltynek CR; Lee CH
Bioorg Med Chem Lett; 2010 Jun; 20(11):3291-4. PubMed ID: 20457518
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and structure-activity relationship of 7-azaindole piperidine derivatives as CCR2 antagonists.
Xia M; Hou C; DeMong D; Pollack S; Pan M; Singer M; Matheis M; Murray W; Cavender D; Wachter M
Bioorg Med Chem Lett; 2008 Dec; 18(24):6468-70. PubMed ID: 18990568
[TBL] [Abstract][Full Text] [Related]
14. CCR5 receptor antagonists: discovery and SAR of novel 4-hydroxypiperidine derivatives.
Lu SF; Chen B; Davey D; Dunning L; Jaroch S; May K; Onuffer J; Phillips G; Subramanyam B; Tseng JL; Wei RG; Wei M; Ye B
Bioorg Med Chem Lett; 2007 Apr; 17(7):1883-7. PubMed ID: 17314043
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and structure-activity relationship of novel CCR2 antagonists.
Kothandaraman S; Donnely KL; Butora G; Jiao R; Pasternak A; Morriello GJ; Goble SD; Zhou C; Mills SG; Maccoss M; Vicario PP; Ayala JM; Demartino JA; Struthers M; Cascieri MA; Yang L
Bioorg Med Chem Lett; 2009 Mar; 19(6):1830-4. PubMed ID: 19237282
[TBL] [Abstract][Full Text] [Related]
16. Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development.
Rami HK; Thompson M; Stemp G; Fell S; Jerman JC; Stevens AJ; Smart D; Sargent B; Sanderson D; Randall AD; Gunthorpe MJ; Davis JB
Bioorg Med Chem Lett; 2006 Jun; 16(12):3287-91. PubMed ID: 16580202
[TBL] [Abstract][Full Text] [Related]
17. From arylureas to biarylamides to aminoquinazolines: discovery of a novel, potent TRPV1 antagonist.
Zheng X; Hodgetts KJ; Brielmann H; Hutchison A; Burkamp F; Brian Jones A; Blurton P; Clarkson R; Chandrasekhar J; Bakthavatchalam R; De Lombaert S; Crandall M; Cortright D; Blum CA
Bioorg Med Chem Lett; 2006 Oct; 16(19):5217-21. PubMed ID: 16870426
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a potent, selective and orally bioavailable 3,9-diazaspiro[5.5]undeca-2-one CCR5 antagonist.
Yang H; Lin XF; Padilla F; Gabriel SD; Heilek G; Ji C; Sankuratri S; deRosier A; Berry P; Rotstein DM
Bioorg Med Chem Lett; 2009 Jan; 19(1):209-13. PubMed ID: 19014885
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of indole-based peptoids as potent noncompetitive antagonists of transient receptor potential vanilloid 1.
Quintanar-Audelo M; Fernández-Carvajal A; Van Den Nest W; Carreño C; Ferrer-Montiel A; Albericio F
J Med Chem; 2007 Nov; 50(24):6133-43. PubMed ID: 17985859
[TBL] [Abstract][Full Text] [Related]
20. Substituted aryl pyrimidines as potent and soluble TRPV1 antagonists.
Stec MM; Bo Y; Chakrabarti PP; Liao L; Ncube M; Tamayo N; Tamir R; Gavva NR; Treanor JJ; Norman MH
Bioorg Med Chem Lett; 2008 Sep; 18(18):5118-22. PubMed ID: 18722118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
